| Previous Close | 71.83 |
| Volume | 2,787,187 |
| Price / Earnings (Forward) | 17.64 |
| Price / Sales | 3.20 |
| Price / Book | 1.59 |
| 52 Weeks Range | |
| TTM Dividend Yield | 0.49% |
| Profit Margin | 11.28% |
| Operating Margin (TTM) | 13.30% |
| Diluted EPS (TTM) | 2.25 |
| Quarterly Revenue Growth (YOY) | 0.60% |
| Quarterly Earnings Growth (YOY) | 41.10% |
| Total Debt/Equity (MRQ) | 23.63% |
| Current Ratio (MRQ) | 2.70 |
| Operating Cash Flow (TTM) | 2.12 B |
| Levered Free Cash Flow (TTM) | 1.18 B |
| Return on Assets (TTM) | 2.74% |
| Return on Equity (TTM) | 5.23% |
News Mood
Positive
- Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
- What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
Negative
AIStockmoo Score
| Value 38% | 4.1 |
| AI Insight info | NA |
| Relative Valuation info | 5.0 |
| Financial Health info | 2.7 |
| Timing 38% | 2.2 |
| AI Technical info | NA |
| Technical Oscillators info | 2.0 |
| Technical Moving Averages info | 2.5 |
| Sentiment 25% | 0.1 |
| Analyst Consensus info | 0.0 |
| News Mood info | 0.2 |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Environment | ×0.90 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | +6.8% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -1.1 |
| Final Score | 2.68 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Alcon Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALC | - | 0.49% | - | 1.59 |
| STVN | - | 0.30% | - | 2.04 |
| BDX | - | 2.20% | - | 2.37 |
| WST | - | 0.37% | - | 9.70 |
| RMD | - | 1.08% | - | 5.56 |
| BLCO | - | - | - | 1.11 |
Select this tab to load the latest available analysis.
|
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Large Growth |
| % Held by Insiders | 0.13% |
| % Held by Institutions | 68.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ako Capital Llp | 30 Jun 2026 | 9,683,004 |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Are Q3 Results Altering The Investment Case For Alcon (SWX:ALC)?
Alcon reported Q3 2026 revenue of US$2.74b and net income of US$260 million, alongside a revised full year 2026 net sales growth outlook of about 6%. The business is relying more on Surgical equipment and Vision Care momentum. At the same time, U.S. premium IOL competition and slightly tighter… |
| 12 Nov 2026 | Yahoo Finance |
Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition
Alcon has delivered mixed share performance in recent years, and the question for you now is whether the current price lines up with what its cash flows can support. With fresh product approvals and an acquisition reshaping its eye care portfolio, the stock invites a closer look at what the… |
| 12 Nov 2026 | Yahoo Finance |
What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?
Alcon (SWX:ALC) reported strong Q3 2026 sales performance, underscoring momentum in its core eye care operations. The firm received US FDA approvals for new intraocular lens products intended for use in cataract and vision correction procedures. Management broadened the portfolio with the… |
| 11 Nov 2026 | Yahoo Finance |
Alcon: 3 Key Takeaways for Long-Term Investors
Alcon's defense of its premium lens franchise against competitor trials is the test that will decide whether its growth holds up. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript
Alcon narrows 2026 guidance as its Neurotech retina deal closes. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc (ALC) (Q3 2026) Earnings Call Highlights: Solid Sales Growth and Margin Expansion ...
Alcon Inc (ALC) delivered 5% sales growth and 15% core EPS growth in Q3 2026, driven by equipment and ocular health strength, while navigating implantable softness and narrowing full-year guidance. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Stocks Fall 4% After Lens Implant Sales Slip and Guidance Narrows
U.S. competition pushed implantables down 2%, and Alcon trimmed the top of its 2026 core EPS growth range. |
| 11 Nov 2026 | Yahoo Finance |
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report. |
| 11 Nov 2026 | Yahoo Finance |
Alcon Inc. Q3 2026 Earnings Call Summary
Moby summary of Alcon Inc.'s Q3 2026 earnings call… |
| 10 Nov 2026 | Yahoo Finance |
Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth
GENEVA, November 10, 2026--Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth… |
| 05 Nov 2026 | Yahoo Finance |
Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026… |
| 05 Nov 2026 | Yahoo Finance |
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
| 04 Nov 2026 | Yahoo Finance |
Alcon Inc. (ALC) Is Positioned to Benefit From Long-Term Healthcare Demand: Here’s the Investment Case
Pershing Square Inc. recently released its Q3 2026 investor letter. A copy of the letter can be downloaded here. The letter reported 13% year-over-year growth in third-quarter fee-related earnings (FRE) to $63.7 million, while distributable earnings (DE) before taxes increased 8% to $61.0 million.… |
| Show more | ||
| TTM Dividend Yield | 0.49% |
| 5Y Average Dividend Yield | 0.20% |
| Payout Ratio | 11.81% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 14 May 2024 | 08 Apr 2024 | 16 May 2024 | 0.2644 Cash |
| 10 May 2023 | 30 Mar 2023 | 12 May 2023 | 0.2356 Cash |
| 29 Apr 2022 | 24 Mar 2022 | 05 May 2022 | 0.2083 Cash |
| 04 May 2021 | 24 Mar 2021 | 06 May 2021 | 0.0909 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.264 | 1 | 0.31 |
| 2023 | 0.236 | 1 | 0.30 |
| 2022 | 0.208 | 1 | 0.30 |
| 2021 | 0.091 | 1 | 0.10 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |